EDIT / Editas (EDIT) Gets FDA's RMAT Tag for Gene Therapy to Treat SCD

Editas Medicine (EDIT) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss more_horizontal

Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 1:00 p.m. ET Dr. Rabi Hanna from Cleveland Clinic Children's to more_horizontal

The FDA bestows Regenerative Medicine Advanced Therapy designation to Editas' (EDIT) gene editing therapy, EDIT-301, for the treatment of severe sickl more_horizontal

Editas uses an untraditional gene-editing technique. The company is in the clinical stage with no approved therapies yet. more_horizontal

Biotech stocks are highly risky even when they're notching successes. Issuing stock and taking out debt are not equivalent risks for shareholders. more_horizontal

Editas Medicine's reduced R&D costs and strong cash position provide operational comfort but necessitate future capital, especially amid looming compe more_horizontal

Stifel upgraded Editas Medicine stock from hold to buy and raised the price target from $9 to $17. The upgrade reflects optimism about Editas' progres more_horizontal

Editas Medicine, Inc. (NASDAQ:EDIT ) Wells Fargo Securities Healthcare Conference Call September 7, 2023 3:00 PM ET Company Participants Gilmore O'Nei more_horizontal